Brainstorm Cell Therapeutics is a biotech company based in New York with a mission to revolutionize the treatment of neurodegenerative diseases. Using its proprietary cell therapy platform, NurOwn, the company is developing autologous cellular therapies that induce bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors that modulate neuroinflammatory and neurodegenerative processes, promote neuronal survival, and enhance neurological function. Brainstorm Cell Therapeutics is currently in the midst of developing NurOwn, which has already completed Phase III clinical trials for amyotrophic lateral sclerosis, as well as a Phase II clinical trial for progressive multiple sclerosis and Alzheimer's disease. The company has also formed a strategic partnership with manufacturing company Catalent to produce NurOwn at scale. Founded in 2000 and formerly known as Golden Hand Resources Inc., Brainstorm Cell Therapeutics is poised to change the future of neurodegenerative disease treatment with its innovative cell therapy approach.
Brainstorm Cell Therapeutics's ticker is BCLI
The company's shares trade on the NASDAQ stock exchange
They are based in Kiryat Aryeh, Petach Tikva
There are 11-50 employees working at Brainstorm Cell Therapeutics
It is brainstorm-cell.com
Brainstorm Cell Therapeutics is in the Healthcare sector
Brainstorm Cell Therapeutics is in the Biotechnology industry
The following five companies are Brainstorm Cell Therapeutics's industry peers: